Laboratory tumor lysis syndrome complicating LBH589 therapy in a patient with acute myeloid leukaemia

Anna Kalff, Jake Shortt, J Farr, Roger McLennan, A Lui, Jeffrey W Scott, Andrew Spencer

Research output: Contribution to journalArticleResearchpeer-review

7 Citations (Scopus)

Abstract

LBH589 is a novel cinnamic hydroxamic acid analog (HAA) pan-histone deacetylase inhibitor (HDACi) currently in early phase clinical development.
Original languageEnglish
Pages (from-to)16 - 17
Number of pages2
JournalHaematologica: the hematology journal
Volume93
Issue number1
DOIs
Publication statusPublished - 2008

Cite this